Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide

I. M. Thompson, C. R. Spence, D. L. Lamm, N. R. Diluzio

Resultado de la investigación: Articlerevisión exhaustiva

7 Citas (Scopus)


Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

Idioma originalEnglish (US)
Páginas (desde-hasta)294-300
Número de páginas7
PublicaciónAmerican Journal of the Medical Sciences
EstadoPublished - 1987

ASJC Scopus subject areas

  • Medicine(all)


Profundice en los temas de investigación de 'Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide'. En conjunto forman una huella única.

Citar esto